X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Initial funding will support project “Gene Mabs: A Scalable, Economic, Gene-Encoded Protective Antibody Platform Against Coronavirus” (HR0011-21-9-0015) to support the development of an STI-2020-encoded Gene MAbTM through Phase 2 clinical studies.
Lead Product(s): STI-2020
Therapeutic Area: Infections and Infectious Diseases Product Name: COVI-AMG
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: DARPA
Deal Size: $34.0 million Upfront Cash: Undisclosed
Deal Type: Funding November 27, 2020
Details:
The platform in synergy with Sorrento’s industry-leading fully human G-MAB™ antibody library has the potential to be the engine for the next-generation, cost-effective in vivo production of antibody therapeutics in patients.
Lead Product(s): STI-2020dna
Therapeutic Area: Infections and Infectious Diseases Product Name: STI-2020dna
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: $19.4 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 02, 2020
Details:
Sorrento plans to accelerate the development of multiple candidates for in vivo gene-encoded expression of Sorrento's antibodies, starting with Sorrento's STI-1499, or COVI-GUARD, which is currently moving through preclinical and manufacturing requirements.
Lead Product(s): STI-1499
Therapeutic Area: Infections and Infectious Diseases Product Name: Covi-Guard
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 24, 2020
Details:
The collaboration will use monoclonal antibodies against SARS-CoV-2 virus discovered and generated by Sorrento that will be encoded into a gene using SmartPharm’s non-viral nanoparticle platform.
Lead Product(s): Gene encoded antibody vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
